Repurposing of FDA approved drugs against uropathogenic Escherichia coli: In silico, in vitro, and in vivo analysis
Authors:
- 30 June 2022
- journal article
- research article
- Published by Elsevier in Microbial Pathogenesis
- Vol. 169, 105665
Abstract
No abstract availableKeywords
Funding Information
- Consejo Superior de Investigaciones Científicas
- Department of Science and Technology, Ministry of Science and Technology, India (DST/INSPIRE/Fellowship/2015/IF150340)
This publication has 39 references indexed in Scilit:
- Open Babel: An open chemical toolboxJournal of Cheminformatics, 2011
- Identification of novel bacterial histidine biosynthesis inhibitors using docking, ensemble rescoring, and whole-cell assaysBioorganic & Medicinal Chemistry, 2010
- Persistence of Uropathogenic Escherichia coli in the Face of Multiple AntibioticsAntimicrobial Agents and Chemotherapy, 2010
- Protein interaction network analysis—Approach for potential drug target identification in Mycobacterium tuberculosisJournal of Theoretical Biology, 2010
- A murine model of urinary tract infectionNature Protocols, 2009
- DrugBank: a knowledgebase for drugs, drug actions and drug targetsNucleic Acids Research, 2007
- Identification ofBurkholderia pseudomalleiGenes Required for the Intracellular Life Cycle and In Vivo VirulenceInfection and Immunity, 2006
- Crystal structure of histidinol phosphate aminotransferase (HisC) from Escherichia coli, and its covalent complex with pyridoxal-5′-phosphate and l-histidinol phosphateJournal of Molecular Biology, 2001
- Miocene Deposits in the Amazonian Foreland BasinScience, 1996
- The estimation of the bactericidal power of the bloodEpidemiology and Infection, 1938